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ABSTRACT
Amyotrophic Lateral Sclerosis (ALS), more commonly referred to as Lou Gehrig’s disease,
is a progressively degenerative neuromuscular disorder affecting both the upper and
lower motor neurons and preferentially affecting males in their forties to seventies.
Although the pathology of ALS has been clearly elucidated elsewhere, the precise
mechanisms by which the disease progresses and the means by which it is acquired
are still poorly understood areas of medicine. Current genomic and proteomic studies
in human and animal models have yielded exciting and promising new findings that
may help elucidate this pathology. It is the purpose of this review article to discuss
the most relevant proposed mechanisms in current medical literature available from
NCBI’s PubMed database as well as to highlight past, present, and future pharmacologic
intervention therapies which have experienced varying degrees of success. This is by no
means an exhaustive assessment of the current literature available; however it should
suffice as a thorough review of the most salient points of modern ALS research.
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INTRODUCTION
Amyotrophic Lateral Sclerosis (ALS), more commonly
referred to as Lou Gehrig’s disease, is a progressively
degenerative neuromuscular disorder affecting
both the upper and lower motor neurons and
preferentially affecting males in their forties to
seventies.1,2 Disease pathogenesis selectively
destroys upper motor neurons (UMN) of the primary
motor cortex and corticospinal tracts in addition to
lower motor neurons (LMN) of the spinal anterior
horns and pontomedullary nuclei.3 The destruction of
these motor neurons results in a loss of coordination
for voluntary movement, often manifesting in a
combination of UMN symptoms including muscle
spasticity, hyperreflexia, increased deep tendon
reflexes, and appearance of immature reflexes such
as Babinski sign in conjunction with LMN symptoms
such as progressive weakness, muscle hypotonia and
atrophy, fasciculations, dysarthria, dysphagia and
eventually respiratory failure. Of these symptoms,
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respiratory failure provides the greatest danger to
the patient, with complications including secondary
bacterial pneumonia compromising patients within
two or three years of diagnosis.2 While the initial
manifestation of these symptoms is seemingly
random in distribution, disease progression often
follows along contiguous neuroanatomic tracts to
varying degrees of severity. The resulting UMN and
LMN symptoms spread at differing rates and manifest
as a consequence of complex somatotopy, creating
complex motor phenotypes that are a hallmark of the
disease.4
The disease can further be subdivided into separate
categories based on the method of inheritance or the
location of symptom onset.1 ALS can present either
sporadically (sporadic ALS, SALS) or along familial
lines (Familial ALS, FALS) with a greater incidence of
sporadic cases in the United States.1,2,5 Furthermore,
symptoms of neurodegeneration can be first noticed
either in the extremities (so-called extremity onset
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ALS) or the tongue (bulbar onset ALS). Extremity
onset ALS is a degeneration of motor neurons
enervating the arms or legs of afflicted individuals
and can first include localized fasciculations, stiffness,
and weakness.1 Patients with affected upper limbs
will notice difficulty completing tasks that require
manual dexterity whereas those with lower limb
onset will notice irregularities in gate and a distinct
dropped foot appearance.1 Disease progression is
often less rapid in those presenting with extremity
ALS than in bulbar cases. Those afflicted with
bulbar onset ALS first notice difficulty speaking or
swallowing, and symptoms quickly spread to the
intercostal muscles and the diaphragm,1 posing
serious respiratory risks that are the most frequent
cause of death in ALS patients.2
LACK OF CONSENSUS
Presently there is a surprising lack of consensus
among the medical community as to how to
categorize familial versus sporadic ALS.5 In an
international study among leaders in ALS research
spanning Europe, India, Australia, and North America
there were inconsistencies in how the distinction
between the two categories were defined. While
some felt the criterion for FALS should include firstdegree relatives including parents or siblings, others
felt the need for second-degree (such as first or
second cousins) or even any family relationship to
warrant the title FALS.5 This distinction goes beyond
nomenclature, as the protocols for diagnosing the
two subfamilies differs substantially. When asked
for comment, participating neurologists claimed to
conduct screens for likely candidate genes implicated
in ALS more frequently in FALS rather than SALS cases
an overwhelming 67.0% to 10.3%, respectively.5
Further complicating the situation is the lack of
clear and agreed upon mechanisms of disease
progression among the medical community. To date
there have been over twelve loci and eight genes6
proposed as causative agents for FALS and among
them exist hundreds of variations. Not surprisingly,
the data available on such a diverse field of study
is vast, with a literary search conducted on NCBI’s
PubMed database yielding close to 19,000 unique
entries for amyotrophic lateral sclerosis. Searches
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were subsequently narrowed to include the terms
“pathology” and “pharmacology,” resulting in 1,034
results. Of these, entries were broadly selected to
represent unique aspects of the body of literature
as a whole. It is the purpose of this review article
to therefore discuss the most relevant proposed
mechanisms in current medical literature as well as
to highlight pharmacologic interventional therapies
with demonstrated or potential future success in
treating ALS.
SUGGESTIVE TRENDS IN DIAGNOSIS
Among the difficulties in treating patients with ALS is
quickly and effectively confirming a diagnosis while
ruling out other possible disease processes. Effective
clinical indicators are contested on the grounds
of validity due to an incomplete understanding of
the disease mechanism however firm agreement
can be reached with regards to symptomology.
For this reason, studies assessing the validity of
measuring tongue strength as a prognosticator
of bulbar onset ALS have yielded strong statistical
significance.7 The effective use of this technique can
help serve as a valuable tool in early, noninvasive
detection of bulbar onset ALS rather than waiting
for more advanced symptoms such as dysarthria and
dysphagia which, once evidenced, are already severe
enough to strongly affect patient survivability. Of the
patients whose tongue strengths were assessed and
who later developed ALS, a statistically significant
proportion deteriorated quickly regardless of site
of onset, indicating a rapid spread of lower motor
neuron degeneration is best marked by assessment
of tongue strength.7,8
On the other side of the clinical spectrum are
highly advanced technologic measurements
using functional Magnetic Resonance Imagery
(fMRI) to assess neuronal activation as a function
of disease progression. Interestingly, analysis of
these techniques suggests there is an observable
signal change in cortical blood oxygen levels
during tasks requiring motor control of the hand
specifically in ALS patients as measured against
controls.9 These changes reflect a neuroplasticity
heretofore unknown in ALS patients, although
limited to those with slowly progressing disease
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symptomology and present only in initial phases of
the disease.10 Still, these findings suggest either that
slow disease progression affords patients the time
to reorganize their own somatotopy or, conversely,
that because patients are able to demonstrate
efficient neuroplasticity they are able to delay
the progression of the disease.9 Whichever the
conclusion, the proven use of fMRI to assess these
neuronal rearrangements proves promising for
future study.
Not all advancements in the understanding of
ALS have been noninvasive; attempts at isolating
novel markers from cerebral spinal fluid (CSF)
in order to obtain objective clinical markers for
disease progression remain one of the forefronts
of ALS research. Degeneration of the blood-CSF
barrier is observed in 46% of ALS patients11 and
offers a suggestive area of clinical assessment.
Still, markers of blood brain barrier impairment,
blood-spinal cord barrier impairment, blood-CSF
barrier impairment, neuroaxonal degeneration,
oxidative stress, neurotransmission, inflammation,
immune activation, and glial activation have not
yet yielded clinically relevant information in the
diagnosis of ALS.11,12 While many of these markers
are present in cases of ALS, they are not exclusive to
this disease and have as yet presented a unique and
reproducible clinical profile. However advancements
have been made in other neurodegenerative
diseases, with reductions in CSF cAMP and cGMP
concentrations in Creutzfeldt-Jakob disease but not
in ALS.12
DISEASE MODELING
Clinical presentations afford unique opportunities to
track the progression of disease while occasionally
affording the chance to test FDA-approved
experimental drugs. However in the interest of
discovery, safer, non-human models must be
selected for study in order to fully elucidate disease
mechanisms and assess pharmacologic intervention
therapies. The gold standard in ALS research remains
the SOD1-G93A transgenic mouse model for
preclinical drug studies. G93A mice possess gainof-function mutations in the Superoxide Dismutase
(SOD1) gene that enhances the generation of
damaging oxygen radicals by Cu,Zn Superoxide
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Dismutase (Cu,Zn SOD). These mutations accurately
reflect symptoms present in human FALS patients13-15
while also affording the luxury of working with a
small, relatively short-lived animal model.
More recently, Pembroke Welsh Corgis and
Boxers with mutations in SOD1 have been
proven to illustrate degenerative myelopathy and
peripheral neuropathy that can serve as a potential
spontaneous model for human ALS. Homozygous
silent mutations in canine SOD1:c.118 are able
to recapitulate symptoms seen in the human
disease process14 and can therefore offer superior
alternatives to the murine model with regards to
surgical study and evaluation of pharmacologic
intervention. SOD mutants of the species
Caenorhabditis elegans have also been generated
for invertebrate study. C. elegans with pan-neuronal
G85R SOD1 expression demonstrate significantly
impaired locomotion and SOD1 aggregates
characteristic of human FALS patients with SOD1
mutations.15 These invertebrate models offer cheaper
alternatives to the higher order research animals
and are free of many of the ethical concerns present
when working with mammals. They are limited in
their application, though, as the Federal Food and
Drug Administration requires drug testing to be
performed on mammals before reaching the public.
PROPOSED MECHANISMS FOR ALS
PATHOGENESIS
Many of the proposed mechanisms currently
under investigation focus on aberrations in
neuronal transcription and translation events
(Table 1). Irregularities in gene sequences either
directly inherited or through predisposition to
environmental insult, shift cellular machinery away
from normal cellular chemistry toward dysfunctional
proteins, hallmark cytosolic aggregations and
plaques containing translationally inert RNA, and
dysregulations in repair mechanisms. As no definitive
etiology for ALS has been established, any or all of
these mechanisms potentially represent processes
in the pathology of disease and may contributes
to a greater interwoven narrative. The following
mechanisms are listed from most well-understood
to the least elucidated although there is significant
overlap in their purported functionality.
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TRANSACTIVE RESPONSE DNA-BINDING PROTEIN
OF 43 KDA (TDP-43)
TDP-43 is a nuclear nucleic acid binding protein
primarily involved in RNA translational events and
metabolism that when irregularly aggregated
in the cytosol represents the major pathological
finding in ALS cell studies.16-18 Pathologic
accumulations demonstrate polyubiquination,
hyperphosphorylation, and irregular cleavage that
likely contributes to the abnormal localization
in affected neurons. Once in the cytosol, mutant
low molecular weight TDP-43 forms β-pleated
sheets not consistent with wild type phenotype19
that are highly dependent on C-terminal domains
demonstrating unusual stability and resistance to
proteasome degradation.20 Granule accumulation
is further promoted by microtubular dysfunction.21
Silent mutations in the 342–366 region affect RNA
splicing regulation promoting the formation of
stress granules whose exact function is as yet poorly
understood. Current research as to whether these
aggregates are protective or the hallmark of cellular
damage are currently under investigation, as are
studies to determine whether a loss of function or
a gain of function mutation is responsible for this
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phenotype. What is known is that a polyubiquinated
TDP-43 aggregate is present in 5% of FALS and 0.52% of SALS cases.22
Regional differences in composition of TDP43 stress granules between neuronal and glial
intracytoplasmic inclusions in the spinal cord and
medulla oblongata of SALS patients and those
found in the basal ganglia and hippocampus
indicate the possibility of heterogeneity in function
or pathology depending on location in the central
nervous system. Among these heterogeneities is
the presence of Smurf2, an upstream effector of E3
ubiqitin ligase that may impact lower motor neuron
function23 and studies suggesting TDP-43 operates
independently of adenosine deaminase on RNA 2
(ADAR2).24
It has been implicated that other proteinaceous
aggregates present during times of cellular strain
serve as scaffolding for the formation of the cytosolic
TDP-43 aggregates.25 These aggregates may follow
a prion-disease-like pathology of replication, acting
as an infectious transmissible protein species that
behaves as a template for misfolding of nascent
wild type proteins.19,26,27 This theory is further
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supported by the presence of described prionrelated glutamine/asparagine (Q/N) rich domain
preferentially seen in prion disease and also
expressed in proteins in ALS patients with mutant
TDP-43. Introduction of these proteins in human
embryonic kidney 293 (HEK293) cells was able to
demonstrate prion seed-like behavior, serving as
a template from which nascent wild type proteins
misfolded to mutant conformations.19,28 Further
studies in murine models with inducible cytosolic
TDP-43 aggregates showed statistically significant
correlation between increasing number of
aggregates and ALS symptomatology, with a reversal
of these symptoms seen on restoration of wild type
TDP-43 function.29
Work in C. elegans models has suggested TDP-43
aggregates serve as a nidus for calcium-dependent
neurodegeneration based on activation of killer
aspartyl proteasomes. These models illustrate
that reductions in intracellular calcium release,
specifically via loss of function mutations in
calreticulin, calnexin, or the ryanodine receptor
or the introduction of intracellular calcium via
ethylene glycol tetraacetic acid or dantroline are
neuroprotective while increases in intracellular
calcium via thapsigargin further exacerbate
neurotoxicity.30 Other mouse studies mimicking
nascent TDP-43 function in deficient cell lines was
able to produce similar findings, with poly(A)binding protein nuclear 1 protein specifically
demonstrating promising results.18,31
TDP-43 has been tentatively linked to a mechanism
involving C9orf72 hexanucleotide expansion and
Fus due to their involvement in RNA binding and
transport32 although these mechanisms are as
yet poorly understood. Data co-localizing TDP43 with FUS aggregates and not with SOD1 has
also been presented.21 Continued study into the
pathogenesis of these aggregates is ongoing,33,34
but is made more difficult with inconsistencies in
the expected phenotypes of genotyped individuals.
In a study by Mosca et al. two blood relatives with
identical genotypes for the TDP-43 locus evidenced
markedly different phenotypes; one sibling had
severe onset ALS whereas the other (and the
two other heterozygotes in the family) remained
unaffected.35 Additionally, TDP-43 aggregates may
not inherently be pathologic, having been located
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in adrenal medulla samples of individuals with and
without ALS.36 Studies have begun elucidating the
possibility that there are potential variations in TDP-43
conformations that can act as strains in pathogenesis
with varying impact on cellular toxicity and disease
pathogenicity.19
CU/ZN SUPEROXIDE DISMUTASE 1 (SOD1)
Mutant SOD1 proteins have been implicated in
extracellular neuronal damage in a number of central
nervous system diseases and are the traditional model
for ALS disease progression. Intracellular damage
is seen in clinical preparations however there is an
equally likely mechanism depicting extracellular
neuronal damage in mutant of SOD1 totaling over
140 variants. Studies have implicated that one of
these variants, apoSOD1, undergoes abnormal folding
to expose its zinc binding site,37 depleting cellular
zinc stores and disrupting zinc homeostasis. In vitro
studies have proven that apoSOD1 expression reduces
viability of target cells but that this is not caused by
the accumulation of cell aggregates as was seen in
the RNA binding proteins listed previously. Further
illustrating the zinc hypothesis are results showing
abatement of cell destruction by the addition of
exogenous zinc and exacerbation by the addition
of known zinc chelators.38 These misfolded SOD1
mutants are increasingly becoming the target for
drug therapy39 due primarily to their speculated early
involvement in a thorough and complex oxidative
damage cascade. Monoclonal antibody experiments
targeting these abnormally folded SOD1 mutants40
have already been demonstrated in murine and
human tissues.
The oxidative stress mechanism of nitrous oxide
and other radical species put forth by proponents
of the SOD1 theory of ALS pathogenesis are well
documented in the literature41 and accommodates a
wide variety of SOD1 mutants with an equally wide
array of cellular effects.42 Among these varieties is
a hyperoxidized variant of SOD1 found to be linked
directly to certain cases of bulbar SALS43 as well as
variants that resulted in decreased O-glycosylation
with β-N-Nacetylglucosamine (O-GlcNAc), an
agent linked to competitive inhibition of cellular
phosphorylation.44 The implication of this reduction
in intracellular O-GlcNAc is a corresponding alteration
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in kinase activity which would cause highly irregular
and cell-wide effects. Many of these mutants have
phenotypic effects directly influenced by copy
number of their aberrant proteins45 which are best
assessed by RT-qPCR.
Similar to TDP-43 and its interrelatedness with Fus
and C9orf72 hexanucleotide expansion, SOD1
mutations have been implicated in pathways with
abnormal RNA binding proteins. Methodologies
proposed by Pokrishevsky et al. purport TDP-43
or Fus aggregates in the cytosol facilitate wild
type SOD1 conformational changes, forming new
and unusual conformations.46 This mechanism
mirrors the already established pattern of prion
diseases, where a misfolded protein serves as a
template for further misfoldings.47 This theory is
generally accepted among the ALS community
as a likely mechanism to explain SALS with SOD1
abnormalities. SOD has also been implicated as an
intermediate in the ER damage cascade, with mutant
SOD1 inappropriately utilizing PDI.48 To even further
complicate the picture of a complete SOD1 cascade,
fibroblast growth factor 2 deficiency prolonged
survival and improved motor performance in ALS
mouse models positive for mutant SOD1 protein.
Accompanying this deficiency was an associated upregulation of glial derived neurotrophic factor and
ciliary neurotrophic factor, two motor system-related
neurotrophic factors.49
FUSED IN SARCOMA (FUS)
FUS is a nuclear RNA binding protein involved
in transcription, post-translational modifications
including RNA splicing and microRNA processing,
and DNA repair.50-52 Aberrations in FUS also
represent one of the primary hallmarks of ALS
cellular pathology, identified in 4-6% of FALS and
0.7-1.8% SALS cases.53 These mutations result
in a hyperosmolar cytosolic environment where
localization of mutant aggregates can occur.51
These aggregates form stress granules similar
to and occasionally co-expressed with TDP-43
and SOD1, where local RNA molecules play an
as yet undetermined role in granule stability.54,55
Furthermore, FUS irregularities disrupt correct
localization of RNA binding proteins, disrupting
nuclear cellular events.56 One current theory posits
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the disruption in FUS localization prevents correct
DNA damage repair, resulting in accumulation of
injurious insults to motor neurons and culminating
in stereotyped ALS symptomology.51 FUS mutants
also express deficiencies in autoregulation, leading
to an increased vulnerability to cellular stress and
degeneration manifesting as axon withdrawal,
synapse dysfunction, and muscular denervation.52
Animal models in Drosophila have demonstrated
that mutations in FUS analog Cabeza (Caz) causes in
vivo toxicity by disrupting neuromuscular junctions
and inducing apoptosis in motor neurons. These
effects are caused by a gain in function mutation
resulting in overexpression of the gene, although
these effects rely on the expression of the protein in
the nucleus. Mutations in the Drosophila homolog
Caz caused retinal degeneration, wing defects,
decreased viability, but most importantly locomotive
impairment in motor neurons and a disruption
of presynaptic terminals at the neuromuscular
junction culminating in motor neuron apoptosis.57
Toxicity is directly correlated to a functional
C-terminus with overexpression as well as deletion
resulting in similar disruptions of locomotion and
neuromuscular junction abnormalities seen in
human ALS patients. Apoptosis of motor neuron cell
bodies was only observed in FUS overexpression
models.57 C-terminal FUS knockout mice have
corroborated the evidence for cytosolic aggregation
seen in Drosophila but were unable to recreate ALS
symptomatology.58 Additional murine models
have been able to demonstrate neuroinflammation,
denervation of neuromuscular junctions, reductions
in functional dendritic cell architecture and total cell
number, and premature host death when gain or loss
of function mutations were introduced to FUS.59
Differences are observed in clinical models versus
those seen in Drosophila, as variants in human FUS
have been proven to signify endoplasmic reticular
(ER) stress. Co-localization with ER markers was seen
in human lumbar spinal cord sections taken from ALS
patients. These markers include protein disulfideisomerase (PDI) as well as calreticulin, whose
aggregates were seen with FUS in motor neuron
cytosols, having translocated from the nucleus. These
findings were consistent with both SALS as well as
FALS and are related to the pathophysiology of SOD1
mutations.48 Patient-derived induced pluripotent
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stem cells transformed into spinal cord neural cells
represent one model of FUS study, where stress
granule aggregation has been correlated to volume
of cytosolic mutant FUS concentrations.60 Utilizing
similar models, DNA damage has been linked to
cytoplasmic accumulations of mutant FUS mediated
by phosphorylation of its N terminus by the DNAdependent protein kinase.61
In contrast to the models discussing aberrant
cytosolic inclusion as a means for pathology,
forced nuclear aggregation of FUS has been able
to demonstrate neuronal cell death in some in
vitro models.62 One study has isolated nuclear
mutant FUS aggregates from ALS fibroblasts
that proved resistant to sodium dodecyl sulfate
denaturation, supporting the possibility that there
are multiple ways to alter FUS functionality to cause
neurodegeneration.56 Similar to TDP-43, FUs has
also been implicated in prion disease-like pathology
with FUS stress granules serving as proteinaceous
templates for misfolding of nascent FUS proteins.63-66
This area of study is not yet fully explored and
represents an ongoing area of research.
CHROMOSOME 9 OPEN READING FRAME
72 (C9ORF72) HEXANUCLEOTIDE REPEAT
EXPANSION
Repeats of the hexanucleotide GGGGCC within the
non-coding portion of C9orf72 on chromosome
9p21 have been reported to cause chromosome
9-linked FALS and frontotemporal dementia (FTD)67
and represent the most common genetic variant
of ALS.68 In an international cross-sectional study
evaluating 4448 ALS patients, 37% of individuals
with FALS are in possession of this mutation,
having as many as 700-1600 copies of the repeat
sequence compared to controls who only have 23
copies.69 Comparable studies have been conducted
in French (46% FALS, 8% SALS),70 Italian (46%
FALS),71 Greek (50% FALS, 8.2% SALS),72 Turkish
(18.3% FALS, 3.1% SALS),73 Slavic (5.9% SALS),74
and Russian (15% FALS, 2.5% SALS)75 populations
testing positive for the GGGGCC repeat. Studies
on Chinese SALS populations have yielded results
indicating this sequence is not correlated to their
patient populations, potentially describing a
predilection for the C9orf72 hexanucleotide repeat
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for Caucasians.76,77
Phylogenetic analyses suggest that the
hexanucleotide first originated in Finland, with all
present day GGGGCC sequences in C9orf72 owing
to a single mutation event 1500 years ago and
representing 46.4% of FALS and 21.1% SALS of the
Finnish population.69,78 The hexanucleotide repeat
leads to the downregulation of the expression
of an alternatively spliced C9orf72 transcript and
to the formation of aberrant nuclear RNA foci.70
The increasing evidence for the presence of this
sequence in FALS cases combined with the late
age of onset for symptoms has led some studies to
evaluate the possibility that this irregularity in RNA
processing caused by the hexanucleotide expansion
may be initially corrected by conventional cellular
repair mechanisms only to eventually overwhelm the
system in later life.79 This expansion itself may not be
inherently irregular but instead trigger pathogenicity
in differentially methylated states80,81 and has
also demonstrated a concordance with abnormal
localization of TDP-43, a hallmark of ALS neuronal
pathology.68 Murine models with induced GGGGCC
sequences have also been constructed, evidencing a
gain of function relationship theorized elsewhere.82,83
Although this sequence provides a possible marker
for over one third of FALS cases, the ethical and
moral implications of how to determine when
patients should or should not be screened for
this repeat are difficult at best to determine. The
concerns about incomplete penetrance raised by
Majounie et al. highlight an average age of disease
onset of 57 with patients only beginning to have
symptom onset well into their nineties.69 The
exact determinants, if there are any, as to whether
or not one should be screened for this repeat are
as yet undetermined.84 Still, the screen can offer
confirmation of disease in the event of a suspected
diagnosis. Ongoing research into reproducible
biomarkers of this region and novel therapeutic
targets are a developing area of study.85
P56S-VESICLE-ASSOCIATED MEMBRANE
PROTEIN-ASSOCIATED PROTEIN B (VAPB)
VAPB is a type II integral membrane protein of the ER
with the free N terminal region projecting into the
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cytosol and is involved in ER to Golgi transport as
well as cellular stress response pathways.86-90 Murine
models have illustrated loss of function mutations
altering the unfolded protein response pathway,
reducing functional myotubule formation91 and
this model has been illustrated in human samples
elsewhere.86,92 Additional murine studies have
demonstrated progressive hyperactivity and motor
impairment due to corticospinal and spinal motor
neuron destruction in VABP transgenic mice.93
Autosomal dominant ALS based on a proline to
serine substitution in the VAPB has been linked
to nuclear envelope deformity, interrupting the
transport of nucleoporin and emerin to the nuclear
envelope.94 VABP has also been shown to suppress
adipocyte lipid differentiation through alterations
in mRNA expression, potentially altering energy
metabolism in a subset of ALS patients.86 However,
despite its involvement in intracellular transport,
VABP mutations have not demonstrated alterations
in protein transport or degradation.95 Of note,
this mutation has not been demonstrated in SALS
patients in Sweden, Portugal and Iceland.96
OPTINEURIN (OPTN)
OPTN is a protein involved in the nuclear factor
kappa B (NF-κB) signaling pathway. Several
mutations have demonstrated inhibited NF-κB
activation and irregular localization of NF-κB proteins
to neuronal and glial cytoplasm97,98 with a 300 bp
region consisting of Alu repeat sequences that are
highly susceptible to novel deletions. Normal OPTN
function has been shown to induce mitochondrial
autophagolysosome formation and serves as an
autophagy receptor, with mutations disrupting its
ability to bind polyubiquinated proteins for transport
to the lysosome for destruction.99-102 TDP-43 and
SOD1 positive cells from SALS patients have also
tested positive for OPTN mutations and suggest
loss of function in OPTN as a contribution to TDP-43
accumulation.97,103-105 OPTN mutants are especially
prevalent in the Japanese population, constituting
the second most mutated gene product associated
with SALS in Japan.106 In contrast, this mutation is
exceptionally rare in British populations where it is
deemed unlikely to be pathologic107 but can serve as
a potential cause of rare rapidly progressive SALS in
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the Dutch.108
EWING SARCOMA BREAKPOINT REGION 1
(EWSR1)
EWSR1 is a RNA binding protein related to FUS and
TDP-43 and a member of the FET protein family.
Due to the fact that this protein is in possession of a
predicted prion domain located on the C-terminus, it
is prone to aggregate formation in both in vitro and
in vivo specimens. It has been demonstrated to have
a toxic effect when expressed109 and was proposed
as an additional candidate for ALS pathogenesis.
Histologic preparations of ALS spinal cord specimens
illustrated aberrant localization in the cytosol
of EWSR1 as opposed to the nucleus in healthy
controls.109-111 One study presented 817 patients
with ALS and 1082 healthy control individuals who
tested positive for mutations in EWSR1 exons 1518, the most pathogenic mutations in the gene
region.109,112 Further work is being conducted
evaluating the relevance of this protein.
SPINOCEREBELLAR ATAXIA TYPE 2 PROTEIN
(ATAXIN2)
ATAXIN2 is another RNA binding protein potentially
linked to ALS pathology, with moderate expansion
of CAG polyglutamine sequences correlating to
increased risk of ALS.113 Based on a cohort of 1538
ALS patients and controls in one Italian study,
polyglutamine sequences that in excess of 31 amino
acids place an individual at elevated risks for SALS
compared to those lacking the repeat sequence.
These trends did not hold true for FALS cases.114 This
was also demonstrated in a cohort study of 375 ALS
patients of Sardinian ancestry with similar findings.115
Aberrant ATAXIN2 accumulations associate with TDP42 and FUS, altering their respective cellular toxicities
and serving as components of cytosolic ALS stress
granule formation.113
EPIGENETICS AND ENVIRONMENT
Recently, studies into the impact of environment
on gene expression have yielded insight into the
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dynamic nature of transcriptional potential. Early
life exposure, for example to in utero hypoxia, heavy
metals, pesticides, tobacco, alcohol, or vitamin
deficiency has been implicated as potential cause
for changes in the genetic transcriptome.116-118
While the precise mechanisms by which such
stressors can contribute specifically to ALS are as
yet poorly understood, some promising studies
have suggested specific methylation events on
proteins such as Kir4.1 glial cell potassium channel
by DNA methyltransferase may play a role in
pathogenesis.119,120 Additionally, individuals with
specific single nucleotide polymorphisms in the MT
gene encoding metallothionein have demonstrated
environmental susceptibility to acquiring ALS.116,121
TREATMENTS AND INTERVENTIONS
To date many studies have been conducted to
determine which treatment interventions pose the
greatest benefit to ALS morbidity and mortality.
The following presents evidence for those methods
that were strongly believed to be
clinically significant, beginning
with those that have demonstrable
improvement on symptomatology
and survival and continuing with
interventions that may prove
promising in the future, then
concluding with several notable
therapies that have not proven
beneficial and should be avoided
in the treatment of ALS (Table 2).
Due to the chronic nature of this
disease, each intervention is part
of a broader scope of treatment
delivered by neurologists,
respiratory therapists, speechlanguage pathologists, physical
therapists, dieticians, social
workers, psychiatrists, nurses, and
other allied health professionals.
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BI-LEVEL INTERMITTENT POSITIVE PRESSURE
(BIPAP)
Due to the current limited understanding of the full
mechanism of disease progression in ALS, the most
important treatment to date remains the effective
administration of assisted respiratory technologies.
Of these, the most useful and well-documented
in the literature is the use of bi-level intermittent
positive pressure (BiPAP) as an effective, noninvasive,
and generally well-tolerated means of ensuring gas
exchange. In a retrospective study conducted at
Hahnemann Hospital, Kleopa et al. evaluated the
efficacy of BiPAP intervention on patient outcomes
and noted significant success in prolonging lifespan
and decreasing symptom onset in ALS patient
populations. Furthermore, the clinic suggests that
patients receive a recommendation for BiPAP during
the first clinical visit where the Forced Vital Capacity
(FVC) reaches 50% of the expected normal. When
used for four hours a day or longer, BiPAP helped
increase survival by 14.2 months.122
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RILUZOLE

BOTULINUM TOXIN (BOTOX®)

Currently there is only one FDA-approved drug for
the treatment of symptoms in ALS patients. This
drug, Riluzole, is a neuroprotective drug that blocks
glutamatergic neurotransmission in the CNS. It
has been proven to inhibit the release of glutamic
acid in vitro and in vivo, though the mechanism
is still speculated and assumed to be due to
inactivation of voltage-dependent sodium channels
on glutamatergic nerve terminals or possibly the
result of a G-protein coupled receptor cascade.
Riluzole also blocks some of the postsynaptic effects
of glutamic acid by noncompetitive blockade of
N-methyl-D-aspartate (NMDA) receptors. The drug
is generally accepted to be a neuroprotectant with
strong anticonvulsant albeit sedative properties.123
In clinical trials, 100 mg daily dose of Riluzole was
able to demonstrate a 9% gain in probability of
surviving one year over control and raised median
survival from 11.8 to 14.8 months. There was also
modest symptom improvement in both bulbar and
extremity onset ALS.124

Botulinum toxin is a paralytic toxin that interferes
with neural transmission by blocking release of
acetylcholine, thus promoting muscle paralysis.
In ALS patients suffering from upper esophageal
sphincter hyperactivity and sialorrhea small clinical
trials have demonstrated measurable increases
in quality of life outcomes through botulinum
administration.132-134 Specifically, patients with UES
hyperactivity experienced decreases in dysphagia for
up to four weeks132 while sialorrhea was reduced for
up to two months.133

DEXTROMETHORPHAN WITH ULTRA LOW-DOSE
QUINIDINE (NUEDEXTA®)
Psuedobulbar affect is a prominent complaint
among patients with ALS, prompting studies
to be completed on the potential benefits of
dextromethorphan. As a selective, noncompetitive
antagonist of the N-methyl-D-aspartate subtype of
the glutamate receptor studies initially attempted to
determine if ALS symptomatology would be reduced
although results showed no measurable decrease
in rate of disease progression.125,126 In conjunction
with ultra low dose quinidine to prevent rapid
metabolism of dextromethorphan, Phase I studies
have demonstrated improvement in peduobulbar
affect. The most common side effects while taking
20 mg dextromethorphan and 10 mg quinidine
although mild included light-headedness, slurred
speech, and fatigue.127-129 Presently long term safety
data is lacking.130,131 Due to difficulties extrapolating
data from small sample sizes, this therapy is not yet
FDA approved.
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RESISTANCE EXERCISE
With muscle weakness representing a significant
cause of morbidity in ALS patients, surprisingly
little objective data has been compiled on the
effectiveness of resistance training in improving
patient quality of life. Data remains largely
equivocal due to existing cohort studies assessing
small numbers of patients, but what data does
exist is promising. One random controlled study
determined improvement based on increased total
ALS Functional Rating Scale as well as increases in
upper and lower limb functionality and has been
corroborated by studies undertaken in Canada.135-137
This is a promising area of study that will hopefully
be developed more fully in the future.
ARIMOCLOMOL
Arimoclomol is an experimental research drug that
amplifies heat shock protein gene expression during
cell stress and has also been useful in prolonging
the lifespan of SOD1 mutant mice. Although its
exact mechanisms are poorly understood, it is
assumed that Arimoclomol amplifies the active
phosphorylated trimer of the transcription factor,
heat shock factor-1. This could potentially increase
available heat shock proteins to help chaperone the
correct folding patterns in mutant SOD1 proteins.138
Efficacy studies are as yet unpublished for patients
but the drug has proven to be well-tolerated and
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safe for human consumption at doses up to 300 mg/
day with evidence strongly supporting the drug be
dosed three times daily.139

demonstrate significant delay in symptom onset,
preservation in muscle strength, and increased
longevity.142

GHRELIN

COENZYME Q10 (COQ10)

Studies from a Korean research team have recently
begun utilizing ghrelin as a potential therapeutic
treatment for ALS, based on the protective effect
ghrelin has on motor neurons experiencing chronic
glutamate excitotoxicity. Ghrelin has been implicated
in the activation of extracellular signal-regulated
kinase 1/2 and phosphatidylinositol-3-kinase/Akt/
glycogen synthase kinase-3β pathways. In order
to confirm ghrelin’s direct involvement in these
cascades, spinal cord cultures were exposed to
exogenous threohydroxyaspartate for three weeks
in order to cause motor neuron degeneration. After
this interval, application of ghrelin was able to
significantly attenuate this degeneration. Ghrelin
was also useful in preventing the expression
of pro-inflammatory cytokines tumor necrosis
factor-α and interleukin-1β, common factors in
neurodegenerative inflammatory processes. From
these studies, it is proposed that ghrelin is acting as a
microglia deactivating factor, promoting the survival
of distressed motor neurons.140

CoQ10 is an antioxidant and mitochondrial cofactor
and as such serves as a promising pharmacologic
intervention. SOD1 mutants suffer from oxidative
damage, suggesting the addition of an antioxidant
may improve the clinical scenario at least slightly,
and the mitochondrial damage seen in some ALS
specimens offered further hope that additional
mitochondrial factors would abate symptoms.
However, during Phase II testing 2,700 mg were
administered daily for nine months and showed
no statistically significant reason to continue on to
Phase III testing. There were no observed side effects
in the patient population taking CoQ10, however
there were no observable benefits, either.143

NIMODIPINE
Nimodipine is a calcium channel blocker
unsuccessful in the therapeutic treatment of ALS that
was theorized to potentially antagonize excitatory
amino acid receptor activation, decrease calcium
entry into damaged neurons, and slow or perhaps
reverse ALS. Unfortunately in a randomized, placebocontrolled, prospective, double-blind crossover
study of nimodipine therapy there was no statistical
significance in the rate of decline of pulmonary
function or limb strength during treatment
compared to control. Additionally, subjects receiving
nimodipine experienced associated side effects
including diarrhea, nausea, and lightheadedness.141
Researchers have abandoned this drug in ALS
treatment and management at the clinical trial
level, however one model utilizing SOD1(G37R)
mice included nimodipine as part of a cocktail
including minocycline and riluzole and was able to
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LITHIUM
Lithium is a monovalent ion that chemically
competes with magnesium to alter activity
of glycogen synthase kinase-3 beta, inositol
monophosphatase, and Akt/β-arrestin2. It
represented a potential candidate drug for ALS
disease modification due to its effects on cellular
oxidative stress, inflammatory pathways, autophagy
and neurotrophism.144 A trial study in 2008 ignited
interest in lithium research for ALS when functional
deterioration was markedly reduced in a cohort
of 16 patients over a fifteen month timeframe.
However meta-analysis of 1100 ALS patients using
lithium was unable to reproduce these findings.145
Phase IIb randomized trials on 67 patients and a
phase III multicenter double-blinded randomized
control study was concluded in 2011 that also was
unable to demonstrate any significant benefit on
survival outcomes.146,147 Although clinical trials
have heavily supported the notion that lithium is no
longer a viable research prospect for the treatment
of ALS, recent studies have demonstrated that
co-administration of riluzole may potentially mask
potential neuroprotective effects of additional
compounds, including lithium which in one trial was
able to reduce ALS neurotoxicity.148
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MINOCYCLINE
Minocycline is a member of the tetracycline class
of antibiotics that has demonstrated potential
neuroprotective effects as a result of its specific
anti-inflammatory mechanisms and regulation of
apoptosis pathways.149,150 After safety trials were
established for patient use along with riluzole,
clinical trials were initiated and early magnetic
resonance imaging of patients on minocycline
showed chemical changes in the precentral gyrus
and brainstem in ALS patients.151,152 A phase III
multicenter double-blinded randomized control
study was completed in 2007 studying 412 ALS
patients who were administered 400 mg minocycline
daily. The results indicated minocycline was actually
harmful to patients, conferring no beneficial effect
for ALS morbidity or mortality while reducing quality
of life.153,154
ERYTHROPOIETIN
Erythropoietin (EPO) is a hormone responsible for
regulation of red blood cell production and was
studied in murine models as a potential disease
modifying agent for ALS, initially improving motor
function and prolonging symptom onset in a dosedependent fashion.155-157 CSF studies revealed lower
EPO concentrations in ALS patients compared to
controls, prompting research into potential efficacy
trials.158 Although safe and well-tolerated initial
studies and suggesting potential reductions in
neurodegeneration, a phase III multicenter doubleblinded randomized control study of 208 patients
was unable to demonstrate change in the course of
ALS pathology.159-161
FUTURE WORK
At present there exists no cure or long-term
treatment regimen for ALS. Lifespans are
lengthened on an order of months with the most
optimistic of therapies and the mechanism of
disease pathogenesis at the cellular level is poorly
understood. Promising studies on the use of
autologous bone marrow mononuclear cells162
have been proven to reduce TDP-43 aggregations
in limited study populations and lumbar intraspinal
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injection of neural stem cells163 have proven safe
for continued Phase II research but as yet show no
motor neuron protection. In addition to such exciting
findings there are also disheartening discoveries
still in their infancy. One proposed explanation for
the failures of pharmacologic therapy has been an
upregulation of ABC drug transporter proteins such
as P-glycoprotein (P-gp) and breast cancer resistance
protein (BCRP) both at mRNA and protein levels
as seen in the SOD1-G93A mouse model.164 This
research clearly illustrates that a cellular resistance
mechanism is being utilized to some degree and
presents its own set of unique challenges in future
treatment strategies.
CONCLUSION
This has been an attempt at summarizing the most
significant findings found presently in the literature
regarding ALS disease progression, mechanism, and
treatment. With the rapidly advancing rate of clinical
trials and cytologic analysis there will invariably
be discoveries that contribute to and potentially
contradict many of the mechanisms proposed.
At present the stress granule theory implicating
the RNA binding proteins TDP-43, SOD1, and FUS
are the most heavily implicated in ALS cellular
pathology and riluzole is the only FDA approved
pharmacologic intervention proven effective for
disease modification and increased quality of life.
Non-pharmacologic interventions such as physical
therapy and BiPAP still present useful adjuncts to
therapy and should be considered when treating ALS
patients. As research continues to find new and more
effective methods of treating ALS, these cellular
pathways will become better known and serve as
the foundation for improved therapies and increased
survival for patients in the future.
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